CONRAD 117
Status:Completed
Phase:I
Principal Investigator(s):Jill Schwartz
Objective:To evaluate TFV/FTC and TFV only fast dissolve vaginal tablets.
Prevention Option(s):Microbicides, MPTs
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionVaginal tablet containing 40 mg of TFV
Mode of DeliveryTablet
ARMsExperimental
DescriptionEmtricitabine (FTC) Alone Vaginal Tablet
Mode of DeliveryTablet
ARMs
DescriptionVaginal tablet with 40 mg TFV and 40 mg FTC
Mode of DeliveryTablet
ARMsExperimental
Official Code:
NCT01694407
Trial Sponsors:
CONRAD
Start Date
End Date
February 28, 2013
January 31, 2014
Enrollment:48
Age range:
18 Years ↔
50 Years
Population:Cisgender Women